Achillion Pharmaceuticals
Achillion Pharmaceuticas | Complement-based Therapeutics.
Launch date
Employees
Market cap
$30.3m
Enterprise valuation
$30m (Public information from Sep 2023)
Share price
$1.1 ACHN
New Haven Connecticut (HQ)
Financials
Estimates*
| USD | 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | <1m | <1m | <1m |
| % growth | - | - | - | - | - | 95 % | 84 % |
| EBITDA | - | - | - | (<1m) | (<1m) | (<1m) | (<1m) |
| % EBITDA margin | - | - | - | - | (1919 %) | (607 %) | (267 %) |
| Profit | - | - | - | (<1m) | (<1m) | (<1m) | (<1m) |
| % profit margin | - | - | - | - | (1750 %) | (587 %) | (269 %) |
| R&D budget | 61.6m | 59.4m | 48.4m | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$41.0m | Late VC | ||
| N/A | N/A | IPO | |
N/A | Spinout | ||
$50.1m | Post IPO Equity | ||
* | N/A | $60.9m | Post IPO Equity |
* | N/A | $134m | Post IPO Equity |
* | N/A | $133m | Post IPO Equity |
* | N/A | $50.5m | Post IPO Equity |
N/A | Acquisition | ||
| Total Funding | $41.0m | ||
Related Content
Recent News about Achillion Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.